Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer

Opinion statement With the development of molecular biology and histology techniques, targeted therapy for non-small cell lung cancer (NSCLC) has emerged, which is highly effective and has marginal side effects. Epidermal growth factor receptor (EGFR) was the first driver gene discovered, whose thre...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in oncology 2023-12, Vol.24 (12), p.1935-1947
Main Authors: Yu, Yinan, Zhao, Jianguo, Xu, Jiaona, Bai, Rui, Gu, Zewei, Chen, Xialin, Wang, Jianfang, Jin, Xueying, Gu, Gaoyang
Format: Article
Language:English
Subjects:
Cancer research
Carcinoma, Non-Small-Cell Lung - pathology
Cardiomyopathy
Cardiotoxicity
Cardiotoxicity - etiology
Cardiotoxicity - prevention & control
Congestive heart failure
Epidermal growth factor receptors
ErbB Receptors - genetics
Histology
Humans
Lung cancer
Lung Neoplasms - pathology
Medicine
Medicine & Public Health
Mutation
Non-small cell lung carcinoma
Oncology
Protein Kinase Inhibitors - adverse effects
Protein-tyrosine kinase
Small cell lung carcinoma
Topical Collection on Cardio-oncology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Opinion statement With the development of molecular biology and histology techniques, targeted therapy for non-small cell lung cancer (NSCLC) has emerged, which is highly effective and has marginal side effects. Epidermal growth factor receptor (EGFR) was the first driver gene discovered, whose three generations of therapeutic use have its characteristics and benefits in clinical practice. However, cardiovascular complications by EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in preclinical studies have been increasingly reported, including heart failure, cardiomyopathy, and QT prolongation, among others. Cardiotoxicity of targeted drugs significantly affects the therapeutic effect of NSCLC and has become the second leading cause of death in NSCLC. The aim of the present review was to recognize the potential cardiotoxicity of third-generation targeted drugs in the treatment of NSCLC and their associated mechanisms to help clinicians identify and prevent it early in the treatment, minimize the cardiotoxicity of targeted drugs, and improve the therapeutic effect of patients.
ISSN:1527-2729
1534-6277
1534-5277
DOI:10.1007/s11864-023-01150-8